A protein or group of proteins that form a Ca 2+ -permeable pore across a membrane, which can be opened or closed by different stimuli.
The study of calcium signalling had its historic roots in investigations focused on excitable cells such as those of the heart, where the calcium ion (Ca 2+ ) was identified as having an important role in contraction more than 130 years ago 1 . Subsequent to those early studies, the Ca 2+ signal was identified as a key regulator of processes in other excitable cells, such as neurons, and in non-excitable cells 2 , including those of the epithelia, where it can control a diverse array of processes such as secretion, proliferation and gene expression 3 . It is therefore understandable that researchers can overlook a protein involved in Ca 2+ homeostasis when it is identified as a protein of interest from cancer biopsies or a short interfering RNA (siRNA) phenotypic screen, or discount Ca 2+ signalling when it is identified as an altered pathway. The ubiquity of the Ca 2+ signal can make it seem that Ca 2+ levels could have no possible role in the selective regulation of oncogenic machinery, and that modulation of a specific Ca 2+ channel or Ca 2+ pump would not be able to avoid drastic adverse effects on non-transformed cells.
However, the ubiquity of the Ca 2+ signal and its ability to differentially regulate a variety of functions simul taneously in the same cell, has driven evolutionary complexity in Ca 2+ signalling that is reliant on specific Ca 2+ channels and pumps, and exchangers 4 . The selective roles of specific proteins that transport Ca 2+ are reflected in the clinical use of pharmacological inhibitors of L-type voltage-gated Ca 2+ channels in the treatment of hypertension 5 , the use of the N-type Ca 2+ channel blocker ziconotide for the treatment of severe and chronic pain 5 , and drug development programmes focused on producing specific pharmacological modulators of Ca 2+ channels to treat a diverse array of conditions 5 . Indeed, the activity of many of the Ca 2+ pumps and channels assessed in cancer can be modulated by pharmacological agents (TABLE 1) .
In the context of cancer, there is often significant remodelling in the expression of proteins directly involved in Ca 2+ signalling 6, 7 . Moreover, important oncogenic machinery is sensitive to regulation by specific Ca 2+ signals 8, 9 . Some proteins that transport Ca 2+ are not just regulators of oncogenic signalling but their altered expression can actually be an initiator of some cancers. Evidence for the direct role of proteins that regu late Ca 2+ transport in the initiation of tumours is seen in mice heterozygous for the loss of the Golgi Ca 2+ pump secretory pathway Ca 2+ -ATPase 1 (SPCA1; encoded by the gene Atp2c1), which show an increased occurrence of squamous cell tumours 10 . In this Review, we provide a general overview of the more complex aspects of Ca 2+ signalling for those outside the field and highlight the diversity of Ca 2+ channels and pumps expressed in human cells. We explore how these proteins regulate specific cellular processes, many of which intersect directly with processes important in cancer progression (for example, proliferation, invasion and cell death). Some of the emerging fields, and areas requiring further study, such as the role of Ca 2+ signalling in the context of the tumour microenvironment (TME), will also be discussed. Finally, new areas that have progressed significantly over the past decade will be described, such as the role of Ca 2+ signalling in controlling pathways important in therapeutic resistance.
Ca
2+ channels and pumps, and exchangers Unlike many other cellular signals, Ca 2+ is not created from an enzymatic reaction or destroyed or converted into an inactive metabolite 11 . What controls the often complex changes in Ca 2+ levels in the cytosol and subcellular organelles are the instruments of Ca 2+ homeostasis -Ca 2+ channels and pumps, and exchangers 11 . These and other proteins involved in Ca 2+ homeostasis and signalling have been described as the Ca 1 Abstract | The calcium signal is a powerful and multifaceted tool by which cells can achieve specific outcomes. Cellular machinery important in tumour progression is often driven or influenced by changes in calcium ions; in some cases this regulation occurs within spatially defined regions. Over the past decade there has been a deeper understanding of how calcium signalling is remodelled in some cancers and the consequences of calcium signalling on key events such as proliferation, invasion and sensitivity to cell death. Specific calcium signalling pathways have also now been identified as playing important roles in the establishment and maintenance of multidrug resistance and the tumour microenvironment. 5 . Transient receptor potential (TRP) ion channels are another diverse family, which includes ion channels with high selectivity for Ca 2+ and potential constitutive activity (for example, TRPV6), as well as temperature-sensitive channels such as the cold sensor TRPM8 and the heat and capsaicin (hot chilli component)-sensitive TRPV1 (REF. 13 ). There are at least 20 ion channels encoded by TRP genes in mammals 14 , and heteromeric associations of channel subunits may produce further functional diversity 13 .
Another important Ca 2+ channel is calcium releaseactivated calcium channel protein 1 (ORAI1), involved in a mechanism known as store-operated calcium entry (SOCE), which is detected by the endoplasmic reticulum (ER) Ca 2+ sensor stromal interaction molecule 1 (STIM1). STIM1 proteins are redistributed upon Ca 2+ store depletion and subsequently interact with ORAI1 proteins found at the plasma membrane, leading to activation of Ca 2+ influx 15 (FIG. 1) . ORAI1-related isoforms include ORAI2 and ORAI3, and heteromeric channels composed of ORAI isoforms may constitute channels with unique properties 16 . Moving from influx to efflux, the efflux of Ca 2+ occurs against a concentration gradient and therefore necessitates an active transport system using ATP cleavage or ion gradients. Plasma membrane Ca 2+ -transporting ATPases (PMCAs) are an example of an efflux pump with four genes that generate a plethora of functionally and regulatory diverse transporters via alternative splicing 17 . Plasmalemmal sodium (Na + )/Ca 2+ exchangers are examples of Ca 2+ efflux mechanisms using the Na + gradient, and include SLC8A1 (also known as NCX1) 18 . Subcellular organelles such as the ER, mito chondria and the Golgi also have mechanisms to increase and decrease Ca 2+ levels including Ca 2+ -permeable /calmodulin-dependent protein kinase II subunit γ (CaMKIIγ) to the nucleus to promote the phosphorylation of cAMP responsive element-binding protein (CREB) and gene transcription; in other cellular systems, localized Ca 2+ increases produced upon the opening of calcium release-activated calcium channel protein 1 (ORAI1) channels is sufficient via a series of signalling pathways (indicated by the small dashed arrow and the plus symbol) to produce the translocation of nuclear factor of activated T cells 1 (NFAT1) to the nucleus. In contrast ORAI1-activated gene transcription via NFAT4 also requires increases in nuclear Ca 2+ (not shown on this figure). Δ denotes changes in a pathway or levels, ↑denotes an increase in levels or activity. IP 3 (FIG. 2) 29 . The temporal gap between these two events represents a further level of control (optimal at 10-20 seconds), and the misaligning of these two events is a feature of a mutation associated with autism spectrum disorder symptoms in patients with the multisystem disorder Timothy syndrome 29 . The aforementioned studies highlight a path for future work in cancer research, especially given the role of Ca 2+ -dependent transcription factors such as the NFATs in various aspects of cancer progression 30 . As will be discussed below, we now have an understanding that the Ca 2+ signalling toolkit is often remodelled with tumorigenesis and that the Ca 2+ signal can regulate key oncogenic and tumour suppressor machinery and pathways. 38 . Similarly, the downregulation of ORAI1 (and consequently SOCE), during the transition of prostate cancer to a hormone-refractory phenotype, bestows protection against diverse apoptosis-inducing pathways, such as those induced by the SERCA inhibitor thapsigargin (TABLE 1) , tumour necrosis factor α (TNFα) and cisplatin and/or oxaliplatin 39 . In the past decade there have been major advances in the understanding of differences between subtypes of the same cancer and the molecular drivers behind alterations in the expression of proteins involved in Ca 2+ homeostasis. For example, TRPV6 is elevated in some but not all breast cancer subtypes 33,40 , and we now know that enhanced copy number of the TRPV6 gene region is a feature of triple-negative breast tumours and also breast cancers of the basal molecular subtype (which have a significant overlap with the triplenegative subtype 41, 42 ). Triple-negative breast cancer is a subtype for which new targeted therapies are required, as this tumour type lacks the oestrogen receptor, a target for anti-oestrogen therapy and HER2 (also known as ERBB2), a target for the monoclonal antibody therapy trastuzumab 41 . Indeed, women with tumours with higher levels of TRPV6 mRNA have decreased survival 42 .
Similarly, in prostate cancer, CACNA1D, the gene encoding Ca V 1.3, was identified as hypomethylated in transmembrane protease serine 2 (TMPRSS2):ETS-related ] CYT ) include ratio-metric probes (dual excitation, for example, Fura-2, or dual emission, for example, Indo-1), which are better suited to account for variances in dye loading 148 , and single-wavelength probes that typically have a superior dynamic range and a greater repertoire of emission and excitation wavelengths, which is often crucial with fluorescently tagged proteins. Single-wavelength probes include Fluo-4 and Rhod-2, which have green and red fluorescence emission, respectively 149, 150 . The development of genetically targeted fluorescent Ca 2+ sensors has accelerated in recent years with a diversity of sensors with good dynamic ranges now available that can be targeted to specific cellular domains or organelles 151, 152 . Small-molecule and genetically targeted Ca 2+ sensors are available with different affinities for Ca ; some are suited to the assessment of the high Ca 2+ levels associated with certain forms of cancer cell death (for example, Fura-2FF 153 ), and those found within intracellular organelles, such as the endoplasmic reticulum (for example, genetically targeted LAR-GECO and similar sensors) 154 . Ca 2+ levels in cells can be assessed using various methods from low-throughput cuvette measurements to ultrahigh-throughput methods using microplates 155 . Imaging with confocal, multi-photon, total internal reflection fluorescence (TIRF) microscopy and fluorescence lifetime imaging microscopy (FLIM) are examples of other approaches [156] [157] [158] [159] . Microscopic assessment can be carried out in cell lines, in isolated tissue or even in vivo 151 , including some studies in tumour masses in skin folds 141 . In addition to these light-based approaches, electrophysiology methods often enable nuanced evaluation and characterization of Ca 2+ influx mechanisms 60 .
gene (ERG) fusion-positive prostate cancers compared with fusion-negative cancers, and as a consequence leads to elevated CACNA1D mRNA levels in TMPRSS2:ERG fusion-positive prostate cancers 43 . These results may be more than just correlative as there is evidence of a role for voltage-gated Ca 2+ channels in processes that may be important in prostate cancer cells. For example, a previous study had shown not only an association between elevated CACNA1D and TMPRSS2-ERG fusion-positive prostate cancers but also that pharmacological inhibition of L-type Ca 2+ channels (which includes Ca V 1.3) suppresses the proliferation of PC3 prostate cancer cells 44 . Moreover, other voltage-gated Ca 2+ channels have been linked to processes in prostate cancer cells, including neuroendocrine-induced differentiation and proliferation [45] [46] [47] [48] . Recent studies have begun to identify a role for microRNA (miRNA) regulation in the remodelling of the expression of specific Ca 2+ transporters in some cancers. This is exemplified by the ability of the cancer-related miR-25 when overexpressed in HeLa cells to dramatically reduce levels of MCU, as well as the association between high levels of miR-25 and low levels of MCU in colon cancer cells, the consequence of which may be reduced sensitivity to apoptosis in some types of cancer 49 . Another example is the association between ORAI1 overexpression (implicated in increased proliferation) and reduced miR-519 levels in some colorectal cancer cell lines and colorectal cancer tissues 50 . Despite the profound changes in the expression of Ca 2+ channels and pumps that can occur in some cancers, it is important to note that changes in expression per se are not necessarily sufficient to make a contribution to oncogenic machinery. For example, the overexpression of a Ca 2+ channel without constitutive activity may have no consequence on proliferative signalling or invasion pathways if it lacks the signals required for its activation. In terms of mechanism, the consequences to Ca 2+ homeostasis of a channel remaining open may be far more significant than changes in its expression.
Activity remodelling. Ca

2+
-sensitive tumour-promoting pathways could be affected even in the absence of altered expression of Ca 2+ channels and pumps by the array of mechanisms regulating the activity of Ca 2+ channels and pumps, including activity-regulating proteins (for example, STIM1), post-translational modifications, splicing and trafficking 36, [51] [52] [53] [54] [55] . For example, the proteolytic cleavage of some Ca 2+ channels and pumps can yield either inactive or more active forms [56] [57] [58] [59] , and in the case of proteolytic cleavage of Ca V 1.2 can produce a C-terminal fragment that acts as a transcription factor 54 . The role of proteolytic cleavage requires further investigation in the context of the potential roles of other Ca 2+ channels and pumps in cancer models.
Further complexity is introduced when considering that activation mechanisms may be altered in a cancer or a cancer subtype. For example, ORAI3 is activated by Ca 2+ store depletion and contributes to SOCE in oestrogen receptor-positive but not in oestrogen receptornegative breast cancer cell lines; however, the mechanism by which this occurs is still not fully understood 60 . In some prostate cancer cells, ORAI3 forms a heteromeric channel with ORAI1 that is activated by arachi donic acid 61 . The cellular signalling diversity offered by dynamic formation of various heteromeric channels compared with monomeric channels may provide some tumours with a growth advantage. Indeed, the switch from ORAI1 monomeric channels to ORAI3-ORAI1 heteromeric channels in prostate cancer cells provides resistance to apoptosis through reduced SOCE (owing to reduced ORAI1 monomers) and increased proliferative signalling via arachidonic acid (as a result of increased ORAI3-ORAI1 heteromers) 61 . Clearly, the Ca 2+ signal can be modulated via diverse mechanisms, not just by changes in expression. In some cases the contribution of ion channels and pumps is attributed to indirect effects or even to functions independent of their own ion transport abilities 36,62-65 . ORAI1-mediated promotion of TRPV6 plasmalemmal localization and subsequent enhancement of prostate cancer cell proliferation 63 is one such example, and cleavage of TRPM7 (an ion channel with a kinase domain) producing kinase domaincontaining fragments capable of chromatin remodelling and subsequent changes in gene expression 66 is another example.
Ca
2+ signal intersection with cancer Given the vital role of Ca 2+ signalling in so many cellular processes 1, 4 it is unsurprising that the Ca 2+ Although expression changes have been previously tabulated 6, 82 , ion channel expression studies have still not yet been assessed sufficiently across different types of cancer to make a comprehensive identification of which channels, if any, may be universally altered. However, it is already clear that some ion channels such as transient receptor potential V6 (TRPV6) have increased expression in several types of cancer. In contrast, calcium release-activated calcium channel protein 1 (ORAI1) is upregulated in basal molecular breast cancers where it may contribute to the invasiveness of this subtype, yet in prostate cancer it is downregulated, which may contribute to apoptotic resistance. Microenvironmental factors (for example, hypoxia, growth factors and pH) may also contribute to expression diversity within tumours and/or during disease progression. signalling is linked to specific cell cycle events, and its importance in cellular proliferation, including the mechanisms by which this regulation occurs, have been previously described 7, 8, 70 . Changes in the level of [Ca 2+ ] CYT occur during cell cycle progression and division [71] [72] [73] , and key steps of the cell cycle are Ca 2+ signal dependent, including early entry into G1 and progression through G1/S and G2/M 8 . The cell cycle events that are Ca 2+ sensitive during cell cycle progression include, but are not limited to, the early induction of FOS, JUN and MYC, the phosphorylation of RB1, the activity of calmodu lin and Ca 2+ /calmodulin-dependent protein kinases (CaMKs) and the activity of various Ca 2+ -dependent transcription factors, including the NFATs, CREB and nuclear factor-κB (NF-κB) 7, 8, 74 . However, increased Ca 2+ is clearly not solely sufficient for proliferation, as it is the nature of the change in cytosolic Ca 2+ that is important in promoting proliferation. More specifically, if increasing Ca 2+ was all that was required for cell proliferation then interventions that increased global or localized Ca 2+ levels would always be pro-proliferative. This is plainly not the case, as pharmacological activation of TRPV4 channels reduces the proliferation of tumour endothelial cells 75 , and silencing of the Ca 2+ efflux pump PMCA2 reduces the proliferation of SKBR3 breast cancer cells 76 . Hence, the role of the Ca 2+ signal and the intersection with proliferation is context dependent.
Angiogenesis
Changes in the expression or activity of specific Ca 2+ channels and pumps in some cancers could bestow increased sensitivity to genetic or pharmacological modulation of these proteins compared with most normal cells in the body. This is particularly the case for Ca 2+ channels and pumps that are not ubiquitously expressed and therefore would not be regarded as universal regulators of cellular proliferation. This is highlighted by the antiproliferative effects of experimental TRPM8 inhibition on prostate cancer cells 77 ; this effect is achieved because of the higher levels of TRPM8 in many prostate cancers compared with the normal prostate and the relatively restricted distribution of this channel in other tissues 32 . Many studies have identified specific Ca 2+ channels or pumps, the reduced expression and/or pharmacological inhibition of which can suppress proliferation of cancer cell lines in vitro and in vivo 6, 8, [78] [79] [80] [81] [82] . One recent study showed that in a mouse model of HER2-overexpressing breast cancer, deletion of PMCA2 resulted in less tumour growth 76 . In addition to suggesting that PMCA2 may be a particularly appro priate therapeutic target for HER2-positive breast cancers, this study also highlights an effective and new approach for future studies wishing to define the role of other Ca 2+ channels and pumps in this and other transgenic animal cancer models.
Ca
2+ signalling in the primary and metastatic TME. The microenvironment of both the primary tumour and metastatic sites is a key player in tumour progression 37, 83 , and the Ca 2+ signal represents a potential means through which the TME (for example, hypoxia, pH, immune cells and cancer-associated fibroblast (CAF) secreted factors) can signal to cancer cells. The important role of Ca 2+ signals in the diverse cell types in the stroma surrounding the primary tumour and at metastatic sites or even in the pre-metastatic niche and how these might contribute to disease progression is still relatively unexplored.
The TME is a driver of angiogenesis, which is required for the maintenance of tumour growth 84 . TRPV4 is crucial for processes important to tumour angiogenesis, as reflected in its upregulation in endothelial cells derived from breast cancers where it facilitates arachidonic acid-mediated increases in [Ca 2+ ] CYT , mechano sensitivity and migration 85, 86 . Indeed, pharmacological activation of TRPV4 enables subtherapeutic doses of cisplatin to become effective in suppressing tumour growth in a syngeneic mouse model of Lewis lung carcinoma by partially reversing abnormal tumour vasculature 86 .
Alterations in Ca
2+ signalling in cancer cells invoked by immune cells and the role of Ca 2+ signalling in the regulation of key processes in immune cells constitute another example of the interplay between Ca 2+ signalling and cells of the TME. C-C motif chemokine 18 (CCL18), a chemokine released from tumour-associated macrophages that promotes breast cancer metastasis, seems to act, at least in part, via Ca 2+ signals elicited downstream of the chemokine receptor membrane-associated phosphatidylinositol transfer protein 3 (PITPNM3) in breast cancer cells 87 . Intervention in ER Ca 2+ signalling in CD4 + T lymphocytes is a proposed mechanism to restore some immune function to the TME 88 . Furthermore, there is a direct role for Ca 2+ signals in regulating cancer cell death induced by cytotoxic T lymphocytes and natural killer cells (reviewed in detail in REF. 89 ).
The Ca 2+ signal interacts with many microenvironmental factors such as oxygen tension, pH, growth factors and other signalling molecules. For example, STIM1 is an important driver of hypoxia-mediated changes that contribute to the progression of hepatocarcinoma; this occurs through a complex mutual interplay whereby STIM1-regulated Ca 2+ influx increases hypoxia-inducible factor-1α (HIF1α) stability and HIF1α in turn regulates STIM1 transcription 90 . . The acidic nature of the TME also alters cytosolic and mitochondrial free Ca 2+ levels via acid-sensing ion channel 1 (ASIC1), the consequence of which is induction of reactive oxygen species (ROS) and activation of NF-κB in breast cancer cells. Indeed, silencing of ASIC1 reduces tumour growth and metastasis in an in vivo mouse xenograft model 92 . Cancer cells that metastasize will have different requirements for survival and growth at the metastatic site compared with those of the primary tumour. An integrated genomic and transcriptomic analysis reported that lower levels of the intracellular Ca 2+ store release channel IP 3 R1 (encoded by the gene ITPR1) is associated with metastasis to the brain but not to other organs 93 . A higher propensity for mutations that were predicted to be deleterious in ITPR1 was also observed in brain metastases arising from breast cancers 93 . The very different growth environment in the brain may be favourable for the selection of breast cancer cells with reduced IP 3 R1 levels and/or activity, which may confer increased resistance to cell death from ER stress or apoptotic stimuli. A direct example of the interplay between cancer cells and the stromal cells of the metastatic niche is found in the establishment of abdominal metastasis in serous ovarian cancer 94 . This metastatic pathway involves Ca 2+ signalling in ovarian cancer cells induced by adipocytes at the metastatic niche. More specifically, Ca 2+ -dependent phosphorylation of salt-inducible kinase 2 (SIK2) in ovarian cancer cells leads to the subsequent activation of fatty acid oxidation and AKT phosphorylation and, as a consequence, augmentation of proliferative and pro-survival pathways 94 . Another example of the potential importance of the metastatic microenvironment and Ca 2+ is seen in the proposal that high levels of extracellular Ca 2+ , due to bone remodelling, are a driver for bone metastasis in cancers that express the extracellular calcium-sensing receptor (CaSR), which is also linked to the proliferation of some cancer cell lines such as BT-474 and MDA-MB-231 breast cancer cells and also PC3 cells 95, 96 . A better understanding of the remodelling of Ca 2+ signalling in cancer cells within different metastatic sites and Ca 2+ signalling induced by stromal cells and events in the metastatic niche may help to define a novel set of molecular therapeutic targets and provide new insights into disease progression. Such studies should continue to be the focus of future research.
Ca
2+ and pathways involved in cancer cell migration, invasion and metastasis. The dissemination of cancer to other organs during metastasis requires the migration and invasion of cancer cells from the primary tumour 37 . Almost every step in the migration and invasion of cancer cells, from processes that influence the first responses to pro-migratory stimuli, to the rate of movement, directional control and the release of enzymes that degrade the extracellular matrix (ECM), has some degree of Ca
2+
Invadopodia
Plasma membrane protrusions associated with degradation of the extracellular matrix, which is important in cancer cell invasion.
Calcium ionophore
A chemical moiety that can facilitate increases in cytosolic free Ca 2+ ([Ca 2+ ] CYT ) independently of Ca 2+ channel activation.
Calcium electroporation
A process whereby an electrical field that increases the permeability of the plasma membrane of cells is applied in the presence of raised extracellular calcium ion concentration.
Necroptosis
A regulated form of necrotic cell death. signal dependence 7, 9, 97 . Here, we highlight some specific studies to provide examples of the mechanisms by which the Ca 2+ signal can contribute to these diverse metastatic processes.
Many pro-migratory signals act on GPCRs that couple to pathways that can mobilize Ca 2+ from internal stores. One example is the activation of the GPCR protease activated receptor 1 (PAR1) on cancer cells by matrix metalloproteinase 1 (MMP1) secreted by fibroblasts of the tumour stoma, which contributes to invasion of breast cancer cells 98 . Studies have consistently shown clear differences in the nature of [Ca 2+ ] CYT signals between the leading and trailing edge of migrating cells, with often highly polarized and localized changes in free Ca 2+ and consistently higher Ca 2+ levels at the trailing edge [99] [100] [101] [102] . In addition to contributing to forward motion by activating contractile proteins at the trailing edge, Ca 2+ signalling is also important in modifications in focal and peripheral adhesion molecules often by affecting turnover via Ca 2+ -dependent phosphorylation or enzymatic cleavage. Furthermore, Ca 2+ changes can also affect key cytoskeletal proteins throughout the cell 9 .
Silencing of components of SOCE (ORAI1 or STIM1) or pharmacological inhibition of this pathway modulates focal adhesion turnover in MDA-MB-231 cells and also reduces the invasiveness of this cell line 103 . Localized Ca 2+ changes may also serve to maintain the polarized cell morphology required for cell migration 104 . Transient (~0.5 seconds) high levels of localized Ca 2+ at the leading edge of migrating cells, termed 'Ca 2+ flickers' , control the direction in which cells move 25 . These studies in human WI-38 lung fibroblasts identified that Ca 2+ influx through TRPM7, in addition to IP 3 -mediated Ca 2+ release from the ER, was crucial in responding to platelet-derived growth factor (PDGF) concentration gradients and subsequent directional migration 25 . The aforementioned studies place the Ca 2+ signal as both the navigator and a key component of the engine in some types of cell motility (FIG. 2) . Further work is now required to define the Ca 2+ channels involved in these specific migration modes in cancer cells; these studies will need to assess cancer cells originating from different organs as different cancers may exploit different types of Ca 2+ channel to achieve and control migration. influx is also important in the formation of invadopodia via ORAI1-dependent Ca 2+ oscillations in melanoma cells, which occurs in part through promotion of SRC (pY416) phosphorylation 106 . Ca 2+ can also contribute to steps in the metastatic cascade through augmentation of other pathways, such as ROS production, which subsequently increases cell migration in lung cancer cells 107 , and cAMP pathways, which increase the invasive ness of a highly metastatic variant of MDA-MB-231 cells in vitro 108 . Further evidence of the involvement of Ca 2+ in cancer cell migration, invasion and metastasis derives from silencing and/or pharmacological inhibition of proteins involved in Ca 2+ signalling, including some of the recently identified molecular components of mitochondrial Ca 2+ regulation, which have been shown to inhibit each of these processes (for example, see REFS 103, 105, 109, 110) . The demonstrated ability to inhibit the migration of MDA-MB-231 cells in vitro and the growth and metastasis of MDA-MB-231 cells to the lungs in vivo in a mouse xenograft model of breast cancer by silencing MCU (in this case likely through lower mitochondrial Ca 2+ levels reducing mitochondrial ROS production and subsequently HIF1α levels) is just one example of studies that have defined roles for specific Ca 2+ -transporting proteins during cancer progression 110 . Specific factors in the TME, such as EGF and hypoxia, induce epithelial to mesenchymal transition (EMT) in cancer cells, which may promote increased invasiveness and therapeutic resistance 111 . Ca 2+ homeostasis is clearly different between the more epithelial and the more mesenchymal cell phenotypes [112] [113] [114] , with attenuation of both SOCE and ATP-mediated changes in [Ca 2+ ] CYT occurring as a consequence of EMT in MDA-MB-468 breast cancer cells 67, [113] [114] [115] . Such changes in Ca 2+ signalling are perhaps expected given the major changes in cellular morphology and protein expression that occur as a result of EMT 111 . However, the Ca 2+ signal itself is integral to the induction of EMT, and ion channels such as TRPM7 and TRPC6 can differentially contribute to the induction of specific EMTassociated markers in different models, such as the regulation of EGF-induced vimentin expression by TRPM7 in MDA-MB-468 cells 67, 116 . It should be noted that the contribution of Ca 2+ channels and pumps to Ca 2+ changes during cancer cell migration and invasion will likely vary between cancer types and with the nature of the stimuli.
The Ca
2+ signal and cancer cell death. Ca 2+ has an important role in pathways relevant to cancer cell death 2, 7, 8, 24, 82, 117, 118 and the remodelling of Ca 2+ channel or pump expression may enable this relationship to be exploited to the benefit of the tumour. For example, in breast cancer cells, the overexpression of PMCA2 bestows increased resistance to cell death by increasing the ability of cells to extrude Ca 2+ after Ca 2+ overload induced by a calcium ionophore 119 . In some cases the contribution of a specific protein involved in Ca 2+ signalling may be through localized or more subtle changes in Ca Accumulation of Ca 2+ in mitochondria has long been associated with apoptotic cell death, with the increases in mitochondrial matrix Ca 2+ induced by some stimuli or stresses contributing to the opening of the relatively non-selective mitochondrial permeability transition pore (a collection of proteins) that contributes to the loss of mitochondrial membrane integrity and the subsequent release of pro-apoptotic factors from mitochondria 117 . Additionally, there is a complex interplay between mitochondria, apoptosis-regulating BCL-2 family members and the Ca 2+ release channels of the ER 126, 127 . Some cancer cells (for example, large B cell lymphoma cells) are sensitive to experimental peptidemediated disruption of the interaction between IP 3 Rs and BCL-2, the consequence of which is cell death 128, 129 . The intersection between Ca 2+ stores, cell death and key players in tumour progression in cancer cells is not restricted to BCL-2. In addition to the association between p53 and ER Ca 2+ levels via effects on SERCA activity discussed above 69 , oncogenic KRAS (KRAS-G13D) seems to attenuate Ca 2+ release from the ER following apoptotic stimuli, which subsequently reduces Ca 2+ accumulation in the mitochondria and promotes colon cancer cell survival 130 . Alternatively, the tumour suppressor BRCA1 can promote Ca 2+ release from the ER during apoptosis through direct effects of IP 3 Rs 131 .
The relationship between the IP 3 R channels of internal Ca 2+ stores and mitochondria is also evident in the regulation of autophagy. When the small constitutive Ca 2+ release from IP 3 Rs of the ER to the mitochondria (which is required for resting mitochondrial bio energetics) is interrupted (such as through pharmacological inhibition of IP 3 Rs by xestospongin B), pro-survival autophagy is induced 132 . However, in at least some cancer cell lines (for example, MCF-7 and T47D breast cancer cells), the disruption of this ER to mitochondria Ca 2+ transfer results in cell death (FIG. 2) 133 . Hence, the basal uptake of Ca 2+ into mitochondria via this pathway is essential for the survival of some cancer cells and this observation adds a new dimension to the selective targeting of malignancies through the targeting of specific and localized Ca 2+ signals. Clearly, there is complex interplay between mitochondria and the ER in the context of Ca 2+ and cell death sensitivity. It appears from the studies described above that many cancers differentially remodel this interaction to achieve a survival advantage. 138 . Importantly these results also identify an alternative therapeutic approach, through targeting TRPC5, to overcome MDR1-mediated drug resistance without global pharmacological inhibition of MDR1 activity. The recent identification that TRPC5 silencing reverses the resistance to the chemotherapeutic agent 5-fluorouracil (5-FU) in HCT-8 and LoVo colorectal cancer cells 139 , suggests that the role of TRPC5 is not confined to breast cancer, and that further exploration of the role of TRPC5 and potentially other Ca 2+ channels in the acquisition and propagation of multidrug resistance would be an exciting avenue to explore.
Targeting the Ca
2+ signal Throughout this Review we have highlighted examples of how the silencing and/or pharmacological inhibition of specific Ca 2+ -permeable ion channels or pumps attenuates the proliferation or invasiveness of cancers. We have also described examples in which Ca 2+ influx through channel activation or calcium electroporation can promote cancer cell death. Indeed, calcium electroporation is currently undergoing a clinical trial for the treatment of cutaneous metastases in comparison with standard electroporation with the chemotherapeutic agent bleomycin (NCT01941901) 140 . Studies have also shown that the chelation of [Ca 2+ ] CYT greatly reduces the induction of apoptosis by photodynamic therapy in vivo, and in at least some cases this effect may be dependent on p53 (REF. 141 ). Besides these observations, other opportunities exist to target the Ca 2+ signal in cancer. For example, a recent study highlights an exciting avenue of exploration and is reflective of the expanse and potential of the Ca 2+ -cancer signalling field to provide novel therapeutic strategies to treat cancer. This study involved an epigenetic screen of more than 1,000 US Food and Drug Administration (FDA)-approved drugs, in addition to drugs already known to induce epigenetic changes. From this screen, 11 drugs with the ability to alter Ca 2+ signalling were identified as being able to reverse epigenetically mediated suppression of tumour suppressor genes in colon cancer cells, likely through CaMKs 142 . The demonstrated ability to pharmacologically modu late Ca 2+ channels and pumps (TABLE 1 ) provides a compelling argument that when Ca 2+ signalling is implicated in a tumour progression pathway, a specific Ca 2+ channel or pump should be seriously considered as a potential drug target. The viability and phenotypes of knockout animals for such identified targets, as well as the effects of pharmacological modulators (if available) in animal models, may act as early indicators of whether such proteins may be appropriate therapeutic targets. Indeed, the repurposing of existing drugs may represent rapid opportunities in this area.
One case in point is the interaction between KRAS and calmodulin and the subsequent suppression of the non-canonical WNT (or WNT-Ca 2+ signalling) pathway, which is crucial for KRAS oncogenesis 143 . Disrupting KRAS-calmodulin binding was described as a unique and 'drug-able' opportunity to target KRAS in pancreatic cancer 143 . However, the identification of Ca 2+ channels that, when activated or inhibited, can regulate the association between calmodulin and KRAS would expand the therapeutic target repertoire of cancer treatments, particularly given the often highly localized role of Ca 2+ channels in the regulation of CaMKII
144
, which is a key conduit in this KRAS malignant pathway 143 . There are clear examples (some of which have already been discussed in this Review), in which a specific isoform of a Ca 2+ channel or pump or a specific heteromeric channel is remodelled or contributes to a particular cancer-relevant pathway. Hence, in many cases the optimal target may be a specific isoform of a Ca 2+ pump, channel or even a specific form of a heteromeric channel. For example, PMCA4 but not PMCA1 silencing promotes ABT-263-mediated cell death in MDA-MB-231 cancer cells, but this is not due to a more important role for PMCA4 in global Ca 2+ regulation 120 . Instead, this effect is likely due to either distinct regulators of PMCA1 and PMCA4, or the different contributions of the isoforms to localized Ca 2+ signalling owing to their potentially different locations on the plasma membrane relative to other proteins and/or their different affinities for the Ca 2+ itself. All of these factors would have an impact on the activation of downstream Ca 2+ -sensitive proteins.
One of the newer areas addressed in this Review is the consideration of Ca 2+ signalling in the context of the microenvironment of the primary tumour and metastatic sites. These areas are a clear opportunity for therapeutic intervention worthy of further assessment. In addition to directly targeting those Ca 2+ channels or pumps within stromal cells, factors in the TME may also be directly targeted to induce Ca 2+ -mediated effects on cancer cells. Such is the case for a SERCA pump inhibitor in the form of a thapsigargin-based protease-activated prodrug (mipsagargin, see TABLE 1), designed to be activated by prostate-specific membrane antigen (PSMA). PSMA is rich in the microenvironment of many solid tumours and, therefore, facilitating localized release of the SERCA pump inhibitor within a tumour would reduce cancer cell viability while avoiding high systemic toxicity 145 . This agent is now in the first stages of clinical assessment for therapy of refractory prostate cancer 146 .
Conclusion
As the numerous examples outlined above attest to, the Ca 2+ signal is not a blunt instrument but is nuanced and contextual and is intricately involved in regulating key cellular mechanisms and pathways. How the signal is modulated and the downstream pathways affected may contribute to outcomes as varied as the evasion of cell death pathways, cancer cell growth, invasion and metastasis, cancer multidrug resistance and the regulation of tumour growth and survival by the primary and metastatic TMEs. The challenge is now to define how best to use the pharmacological opportunities offered by Ca 2+ channels and pumps to selectively target these processes and improve patient outcomes.
